Hutchmed price target lowered to $21 from $22 at BofA

1 week ago 15

TipRanks

Sat, March 7, 2026 astatine 7:16 AM CST 1 min read

BofA expert Alec Stranahan lowered the firm’s price target connected Hutchmed (HCM) to $21 from $22 and keeps a Buy standing connected the shares. The steadfast says Hutchmed’s FY25 people “offered immoderate affirmative steps guardant aft a weaker 1H25.” Directional commentary astir fruquintinib denotation enlargement successful 2026 and expanding the fig of Fruzaqla markets bolsters the firm’s assurance that Hutchmed tin conscionable their 2026 guidance for Oncology/Immunology, the expert tells investors.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected HCM:

Disclaimer & DisclosureReport an Issue

Hutchmed reports work of SACHI results successful The Lancet
Hutchmed says Phase III of ESLIM-02 proceedings met superior endpoint
Hutchmed terms people lowered to $22 from $25 astatine BofA

Read Entire Article